Henceforth, WHO classification was updated by incorporating subcategories based on recurrent cytogenetic abnormalities and mutations such as AML with mutated NPM1 and CEBPA as full entities and mutated RUNX1 as provisional entity in the revised 2016 classification (Arber et al., 2016). Here, RUNX1 is linked to acute myeloid leukemia.